1. CAPR stock dropped 30% following FDA advisory meeting cancellation. 2. FDA shows concerns over effectiveness of Deramiocel for Duchenne Muscular Dystrophy. 3. BLA for Deramiocel under priority review, action date August 31, 2025. 4. 1.9 million shares traded, below the average of 2.41 million. 5. Ongoing tensions at FDA add uncertainty to Capricor's regulatory prospects.
The cancellation of the advisory meeting significantly reduces investor confidence, akin to previous cases like GW Pharmaceuticals’ Sativex failing FDA panel. A 30% drop indicates market panic and loss of momentum.
The article details critical regulatory actions affecting CAPR, directly impacting investor sentiment and stock performance.
Immediate repercussions observed in CAPR stock, suggesting negative sentiment will persist until clearer regulatory guidance is provided, similar to other biotech companies facing advisory meeting cancellations.